Key facts
- This page summarizes Chris Degnan's Form 4 filing for UroGen Pharma Ltd. (URGN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Oct 2025, 13:37.
Chris Degnan - 08 Oct 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- URGN
- Reported as of
- 08 Oct 2025
- Net transaction value
- -$37,121
- SEC form
- 4
- Accepted by SEC
- 09 Oct 2025, 13:37:33 UTC
- Prior SEC filing
- 09 Oct 2024
- Next SEC filing
- 03 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason D. Smith, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chris Degnan filed Form 4 for UroGen Pharma Ltd. (URGN) on 09 Oct 2025.
Change
- Previous filing in this sequence was filed on 09 Oct 2024.
- Current net transaction value: -$37,121.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001741968
Primary reporting owner
Degnan Chris
- Relationship
- Chief Financial Officer
- Address
- 400 ALEXANDER PARK DRIVE, PRINCETON
- Signature
- /s/ Jason D. Smith, Attorney-in-Fact
- Signature date
- 09 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
URGN
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +4,483
- Change %
- Price
- Shares after
- 4,483
- Date
- 08 Oct 2025
- Ownership
- Direct
- Footnotes
- F1
URGN
transaction
Ordinary Shares
Sale
- Transaction value
- $37,121
- Shares
- -2,203
- Change %
- -49%
- Price
- $16.85
- Shares after
- 2,280
- Date
- 08 Oct 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
URGN
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,483
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 8,967
- Date
- 08 Oct 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 4,483
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
Footnote F2
Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
Footnote F3
The reporting person was granted RSUs on October 8, 2024 representing 13,450 ordinary shares. The RSUs will vest in three equal annual installments from October 8, 2025.